NCT05694533View on ClinicalTrials.gov

Study of Potential CYP3A4 Induction by INDV-2000 in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 16, 2023

Primary Completion Date

April 6, 2023

Study Completion Date

May 1, 2023

Conditions
Healthy
Interventions
DRUG

INDV-2000

Capsules administered orally twice a day

DRUG

Midazolam

Midazolam syrup administered orally on Days 1 and 15

Trial Locations (1)

85283

Celerion, Tempe

Sponsors

Lead Sponsor

Indivior Inc.
All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Indivior Inc.

INDUSTRY

NCT05694533 - Study of Potential CYP3A4 Induction by INDV-2000 in Healthy Adults | Biotech Hunter | Biotech Hunter